Evidence map›Paper›PMID 32751954›Full record

ArticleBrain sciences2020

Distinguishing and Biochemical Phenotype Analysis of Epilepsy Patients Using a Novel Serum Profiling Platform.

Jay S Hanas, James R S Hocker, Christian Vannarath, Betcy Evangeline, Vasudevan Prabhakaran, Anna Oommen, James Couch, Michael Anderson, Vedantam Rajshekhar, Hélène Carabin and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jay S HanasDepartment of Biochemistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.ORCID 0000-0003-1922-5333
James R S HockerDepartment of Biochemistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.ORCID 0000-0002-7111-9119
Christian VannarathDepartment of Biochemistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.ORCID 0000-0003-4725-6794
Betcy EvangelineDepartment of Neurological Sciences, Christian Medical College, Vellore 632004, India.
Vasudevan PrabhakaranDepartment of Neurological Sciences, Christian Medical College, Vellore 632004, India.ORCID 0000-0002-5973-7627
Anna OommenDepartment of Neurological Sciences, Christian Medical College, Vellore 632004, India.
James CouchDepartment of Neurology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Michael AndersonDepartment of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Vedantam RajshekharDepartment of Neurological Sciences, Christian Medical College, Vellore 632004, India.
Hélène CarabinDepartment of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Douglas DrevetsDepartment of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

Funding

Understanding the inflammatory processes of neurocysticercosis: a US-India partneR21NS077466 · NINDS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CARABIN, HELENE · 2011 to 2013
$394k
National Institute of Neurological Diseases and Stroke in the U.S. R21NS077466The Department of Biotechnology in India under the U.S.-India Bilateral Brain Research Collaborative Partnerships (U.S. - India BRCP). BT/MB/BRCP/06/2011The National Institute of Neurological Diseases and Stroke and the Fogarty International Center under the Global Brain and Nervous System Disorders Research Across the Lifespan program. R01NS098891U.S. Department of Defense W81XWH-16-1-0295Veterans Administration Research and Education Fund 829-VREF
6 · The paper itself

Abstract

Diagnosis of non-symptomatic epilepsy includes a history of two or more seizures and brain imaging to rule out structural changes like trauma, tumor, infection. Such analysis can be problematic. It is important to develop capabilities to help identify non-symptomatic epilepsy in order to better monitor and understand the condition. This understanding could lead to improved diagnostics and therapeutics. Serum mass peak profiling was performed using electrospray ionization mass spectrometry (ESI-MS). A comparison of sera mass peaks between epilepsy and control groups was performed via leave one [serum sample] out cross-validation (LOOCV). MS/MS peptide analysis was performed on serum mass peaks to compare epilepsy patient and control groups. LOOCV identified significant differences between the epilepsy patient group and control group (

Indexed as

epilepsymass spectrometrymonitoringphenotype analysisserum profiling

Identifiers

PMID32751954
PMCPMC7464346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.